Radioactive Yttrium-90 (Y-90) was injected into 163 joints. Of these patien
ts 115 were persons with haemophilia and they suffered from recurrent haema
rthroses. The median age at the time of the initial exposure to 90Y was bet
ween 11 and 15 years and the median follow-up period 11 years. Over 80% of
the patients with haemophilia reported a decrease in the number of haemarth
roses and 15% stopped bleeding altogether in the treated articulation. The
safety of this modality of management has been reported and hence the patie
nts age should not be regarded as a criteria.